ALK and lung carcinoma: To compare the performance of the conventional AUC-based drug sensitivity test and the proposed CODRP drug sensitivity test algorithm, PDOs from ALK-positive and negative lung cancers were tested for three ALK-targeted drugs (crizotinib, alectinib, and brigatinib).